Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, Marla C Dubinsky, Marc Ferrante, Peter M Irving, Nikolaos Kamperidis, Taku Kobayashi, Paulo G Kotze, Jo Lambert, Nurulamin M Noor, Xavier Roblin, Giulia Roda, Niels Vande Casteele, Andres J Yarur, Naila Arebi, Silvio Danese, Stephane Paul, William J Sandborn, Séverine Vermeire, Adam S Cheifetz, Laurent Peyrin-Biroulet
Topics & Concepts
MedicineTherapeutic drug monitoringInflammatory bowel diseaseIntensive care medicineRheumatoid arthritisCertolizumab pegolPharmacogeneticsDrugDisease monitoringInflammatory Bowel DiseasesClinical trialInflammatory arthritisInfliximabDiseaseAdalimumabSampling (signal processing)Drug responseDrug developmentVedolizumabDosingUlcerative colitisPharmacokineticsCrohn's diseaseIdentification (biology)MEDLINEPharmacologyArthritisAntirheumatic AgentsEfficacyRisk assessmentImmunologyInflammatory Bowel DiseaseBiosimilars and Bioanalytical MethodsRheumatoid Arthritis Research and Therapies